Q-omics provides the consensus-scored SNORD56B profile across patient tissues and cancer cell-line models. SNORD56B expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNORD56B is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, SNORD56B RNA expression shows 6,707 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight ACC, LUSC, and COAD as cancer lineages where SNORD56B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD56B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD56B survival associations across molecular data types. SNORD56B RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD56B RNA expression–survival associations across cancer types. High SNORD56B expression shows unfavorable associations in ACC, KICH, KIRC, CESC and COAD, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNORD56B RNA expression.
This table summarizes SNORD56B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD56B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD56B shows lower tumor expression in LUSC. The LUSC box plot shows higher SNORD56B RNA expression in normal versus tumor tissue (log2 FC = −0.162, t-test p = .008).
This table shows molecular features associated with SNORD56B in patient tissues and cancer cell lines. In patient samples, SNORD56B shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
